Abstract
Hemophagocytic syndrome (HPS) is a rare clinical disorder characterized by persistent and ineffective activation of the immune system, leading to a severe systemic inflammatory response. Lymphoma-associated hemophagocytic syndrome (LAHS) refers to HPS caused either by lymphoma itself or by immunosuppression during lymphoma chemotherapy at present, there is no standardized consensus on the diagnosis and treatment of LAHS, both domestically and internationally. After remission induced by combination chemotherapy, hematopoietic stem cell transplantation (HSCT) is a commonly used treatment approach. This paper reviews the latest advancements in the diagnosis and treatment of LAHS, providing a reference for its clinical management.